Advertisement


Joannie M. Ivory, MD, MSPH, and Lisa A. Carey, MD, on PAM50 Subtype and 21-Gene Recurrence Scores in Younger and Black Women With Breast Cancer

2022 San Antonio Breast Cancer Symposium

Advertisement

Lisa A. Carey, MD, and Joannie M. Ivory, MD, MSPH, both of the University of North Carolina at Chapel Hill, discuss the higher frequency and treatment implications of nonluminal A or high-risk tumors in Black and younger women. In this study, PAM50 and 21-gene assays revealed different demographic patterns by race and age (Abstract PD1-08).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Lisa Carey, MD: One of the pleasures of working at the University of North Carolina has been the Carolina Breast Cancer Study, which has given us enormous information over a number of decades about breast cancer risk and behavior, particularly in young women and people of color, specifically Black women. More recently, the biology has been even further defined with some efforts to look at genomic assays by race and by age. Joannie, you've been part of an analysis that came out in San Antonio this year. Do you want to talk a little bit about that? Joannie Ivory, MD: Absolutely. We did a update of the Carolina Breast Cancer Study analysis. What that showed was that women who were Black had a higher frequency of non-luminal A tumors, as well as younger women. They had a higher frequency of non-luminal A tumors, as well. The importance of this is that this can have treatment implications, because as we know, the tumors that are non-luminal A, they tend to be more endocrine-resistant. Taken into consideration, this was all done in early-stage breast cancer. What I think we need to do is expand and actually look at these relationships in metastatic breast cancer. Lisa Carey, MD: Joannie, let me push you a little bit on that. Early breast cancer, the non-luminal As include luminal B, HER2-enriched basal-like. Joannie Ivory, MD: Mm-hmm. Lisa Carey, MD: Can you talk a little bit more about what does it mean to be luminal B or HER2-enriched or basal-like? Joannie Ivory, MD: Yeah. The most common breast cancer is ER-positive, HER2-negative breast cancer. Usually, that correlates with luminal A tumors. When you get more so to the basal-like tumors, they pretty much behave like triple-negative breast cancer, and so that's why they're a little bit more resistant to endocrine therapy. I think this is an emergent field where we are actually starting to use this to assess whether or not this can guide treatment in the future. Lisa Carey, MD: Yeah, I mean some studies are testing whether or not, in fact, in basal-like tumors, you should be using chemotherapy, regardless of what the receptor phenotype is. I should be very clear that the analysis that was done of the Carolina Breast Cancer Study was only in the hormone receptor-positive, HER2-negative group, where this starts to become particularly important to know. Talk a little bit about the Lineberger study called HARMONY, and what that's doing and your part of that. Joannie Ivory, MD: The HARMONY trial at Lineberger, it's pretty much an interventional study at this single institution. What we're doing is we're determining the intrinsic subtypes of the tumor in the metastatic setting. What we're going to do is we're going to get the intrinsic subtype of the primary tumor and also of the metastatic tumor and see if there's a concordance between the two. Then what we're also going to do is that once the patient goes and see their provider, they're going to treat the patient as they normally would, but then we're going to give the treating providers the intrinsic subtype information, and then do a survey and see how this changes their decision in a second-line setting. Lisa Carey, MD: Right. I think the implication here is if you see more non-luminal As the Carolina Breast Cancer Study showed in the early setting, if you're seeing this also in the metastatics, saying we may see even more discordance in the metastatic setting in Black women, and parenthetically, also young women. Joannie Ivory, MD: Absolutely. This is also something that I will be studying myself for my ASCO YIA research proposal where we're actually going to look at the race and age relationship of the intrinsic subtypes in the HARMONY trial to see if the same relationship that was seen in early breast cancer is upheld in a metastatic setting. Lisa Carey, MD: Fantastic, fantastic. I think it's going to be super important, and I think in so many of the trials, things that were shown at San Antonio, there's so few Black women represented in the trials, and so we really have to use our population-based studies to illuminate this a little bit more. Joannie, thank you so much for everything you're doing. I look forward to these really interesting analyses. Joannie Ivory, MD: Thank you.

Related Videos

Breast Cancer

Per Karlsson, MD, PhD: New Data on Breast-Conserving Surgery, With or Without Radiotherapy

Per Karlsson, MD, PhD, of Sweden’s University of Gothenburg and the Sahlgrenska Comprehensive Cancer Center, discusses results from the POLAR study, which was a meta-analysis of three clinical trials of breast-conserving surgery with or without radiotherapy. POLAR is the first genomic classifier that appears not only to be prognostic for locoregional recurrence, but also predictive of radiotherapy benefit. Although patients with breast cancer who had a high POLAR score benefited from radiotherapy, patients with a low score did not, and may be candidates for omission of radiotherapy after breast-conserving surgery (Abstract GS4-03).

Judy C. Boughey, MD, on New Findings on the Impact of Breast Conservation Therapy on Local Recurrence

Judy C. Boughey, MD, of Mayo Clinic, talks about why breast-conserving therapy may be a treatment option for some patients with multiple breast lesions. For most patients who present with two or three sites of cancer in one breast, mastectomy is recommended. But results from the ACOSOG Z11102 (Alliance) suggest that for women with multiple ipsilateral breast cancer, breast-conserving surgery with adjuvant radiation therapy and lumpectomy site boosts may be beneficial (Abstract GS4-01).

Breast Cancer

Mafalda Oliveira, MD, PhD, on Camizestrant vs Fulvestrant in Advanced Breast Cancer: New Phase II Results

Mafalda Oliveira, MD, PhD, of Spain’s Vall d’Hebron University Hospital and Institute of Oncology, discusses findings from the SERENA-2 trial, which compared the next-generation selective estrogen receptor degrader camizestrant to fulvestrant in patients with hormone receptor–positive, HER2-negative breast cancer. Camizestrant, which can be taken as a daily pill (as opposed to fulvestrant, which must be given via injection), improved progression-free survival by up to 42% (Abstract GS3-02).

 

Breast Cancer

Aditya Bardia, MD, MPH, on Elacestrant vs Standard-of-Care Endocrine Therapy in ER-Positive, HER2-Negative Breast Cancer

Aditya Bardia, MD, MPH, of Massachusetts General Hospital, discusses results from the phase III EMERALD trial, the first study to demonstrate improved progression-free survival vs standard of care in estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer with one to two prior lines of endocrine treatment, with or without one line of chemotherapy. This finding applied to all patients in the study, including the subgroup with ESR1 mutations (Abstract GS3-01).

Breast Cancer

Nicholas C. Turner, MD, PhD, on New Data on Capivasertib and Fulvestrant for Advanced Breast Cancer

Nicholas C. Turner, MD, PhD, of London’s Institute of Cancer Research and The Royal Marsden, discusses phase III results from the CAPItello-291 clinical trial, which showed that in patients with hormone receptor–positive, HER2-negative tumors resistant to aromatase inhibitors, adding the investigational AKT inhibitor capivasertib to fulvestrant doubled the median progression-free survival compared with placebo plus fulvestrant (Abstract GS3-04).

Advertisement

Advertisement




Advertisement